The National Institute of General Medical Sciences (NIGMS) of The National Institutes of Health (NIH) has awarded a grant expected to total $11.3 million to fund phase 2 of southern Nevada’s first Center of Biomedical Research Excellence (COBRE): The Center for Neurodegeneration and Translational Neuroscience (CNTN). The funding will allow for an additional five years of continued collaboration between Cleveland Clinic Lou Ruvo Center for Brain Health and the University of Nevada, Las Vegas (UNLV) to enhance neuroscience research infrastructure in southern Nevada. The award is co-led by Aaron Ritter, M.D., of the Lou Ruvo Center for Brain Health and Jefferson Kinney, Ph.D. of the Department of Brain Health at UNLV.

UNLV and the Cleveland Clinic Lou Ruvo Center for Brain Health have received an $11.3 million federal grant to continue their joint research into brain diseases.

UNLV and the Cleveland Clinic Lou Ruvo Center for Brain Health have received an $11.3 million federal grant for the next phase of their joint research into the causes of degenerative brain diseases such as Alzheimer’s and potential treatments.

A recent proposal that Medicare only cover Aduhelm (aducanumab) for patients with Alzheimer’s disease who are enrolled in clinical trials is needlessly restrictive, and will prevent many people from accessing a medication that may be able to help them.

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

This year has been a major year in the field of Alzheimer disease (AD), with several promising therapies moving forward and the first FDA approval in almost 2 decades.

It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.

Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.

The cause of Alzheimer’s was supposedly simple.

Alzheimer’s treatments seemed unlikely just a few months ago.